| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.68 [0.47, 0.99] | | < 1 | | 0% | 1 study (1/-) | 97.8 % | NA | not evaluable | | crucial | - |
| deaths (OS) (extension) | 0.72 [0.59, 0.88] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.55 [0.45, 0.68] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.52 [0.42, 0.65] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 2.03 [1.36, 3.03] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.66 [0.76, 3.60] | | < 1 | | 0% | 1 study (1/-) | 10.1 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 1.21 [0.85, 1.72] | | < 1 | | 0% | 1 study (1/-) | 14.5 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 0.79 [0.39, 1.60] | | < 1 | | 0% | 1 study (1/-) | 74.6 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.67 [1.01, 2.74] | | < 1 | | 0% | 1 study (1/-) | 2.2 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 1.37 [0.95, 1.97] | | < 1 | | 0% | 1 study (1/-) | 4.6 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 1.84 [1.33, 2.53] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 2.99 [1.50, 5.98] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 1.15 [0.30, 4.49] | | < 1 | | 0% | 1 study (1/-) | 42.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Asthenia TRAE (grade 3-4) | 2.97 [0.15, 59.50] | | < 1 | | 0% | 1 study (1/-) | 24.1 % | NA | not evaluable | | non important | - |
| Cough TRAE (grade 3-4) | 0.49 [0.01, 24.88] | | < 1 | | 0% | 1 study (1/-) | 63.6 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.25 [0.01, 7.35] | | < 1 | | 0% | 1 study (1/-) | 78.8 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.49 [0.07, 3.50] | | < 1 | | 0% | 1 study (1/-) | 76.0 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 2.97 [0.15, 59.50] | | < 1 | | 0% | 1 study (1/-) | 24.1 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.49 [0.01, 24.88] | | < 1 | | 0% | 1 study (1/-) | 63.6 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.99 [0.03, 29.48] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.49 [0.01, 24.88] | | < 1 | | 0% | 1 study (1/-) | 63.6 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.65 [0.22, 1.90] | | < 1 | | 0% | 1 study (1/-) | 78.4 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.49 [0.01, 24.88] | | < 1 | | 0% | 1 study (1/-) | 63.6 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.99 [0.03, 29.48] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Anaemia AE (grade 3-4) | 0.86 [0.35, 2.07] | | < 1 | | 0% | 1 study (1/-) | 63.3 % | NA | not evaluable | | non important | - |
| Arthralgia AE (grade 3-4) | 0.49 [0.01, 24.88] | | < 1 | | 0% | 1 study (1/-) | 63.6 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 1.48 [0.15, 14.32] | | < 1 | | 0% | 1 study (1/-) | 36.8 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 0.49 [0.03, 7.89] | | < 1 | | 0% | 1 study (1/-) | 69.0 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.99 [0.03, 29.48] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.99 [0.09, 10.92] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 0.24 [0.02, 2.71] | | < 1 | | 0% | 1 study (1/-) | 87.3 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 0.49 [0.10, 2.44] | | < 1 | | 0% | 1 study (1/-) | 80.7 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 0.57 [0.19, 1.71] | | < 1 | | 0% | 1 study (1/-) | 84.2 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.16 [0.02, 1.57] | | < 1 | | 0% | 1 study (1/-) | 94.1 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 0.24 [0.02, 2.71] | | < 1 | | 0% | 1 study (1/-) | 87.3 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 0.99 [0.03, 29.48] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.49 [0.01, 24.88] | | < 1 | | 0% | 1 study (1/-) | 63.6 % | NA | not evaluable | | non important | - |
| Pneumonia AE (grade 3-4) | 1.16 [0.52, 2.57] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
| Pneumonitis AE (grade 3-4) | 1.32 [0.51, 3.43] | | < 1 | | 0% | 1 study (1/-) | 28.2 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.49 [0.01, 24.88] | | < 1 | | 0% | 1 study (1/-) | 63.6 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 0.99 [0.03, 29.48] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 0.99 [0.03, 29.48] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
